fashion -WSS

fashion

author：fashion 2025-10-02 23:31:22 - browse：882

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Headspace, Meta partner to launch VR meditation app for Quest

hotspot

WSS

Infectious disease expert Jeanne Marrazzo assumes Fauci role

RSV shot was 90% effective at preventing hospitalizations in kids

CDC marks new Covid

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

hotspot

fashion

focus

Wildfire smoke exposes gaps in outdoor worker protections

Change Healthcare cyberattack prompts Medicare loan program

23andMe had bad news about my health. I wish a person had delivered it

National panel will explore requiring free Covid tests

What does generative AI mean for health care? We asked experts

The high personal cost of affirmative action for Black doctors

Malaria cases in Florida and Texas: Here’s what you need to know

UnitedHealth quietly bought dozens of outpatient centers

Bright Health sells Medicare Advantage business to Molina

The Readout: Amylyx, Alumis, and Lundbeck drug updates

hotspot

The high personal cost of affirmative action for Black doctors

Lawsuit alleges UnitedHealth Group unit illegally denied claims

How to bring more disabled researchers into academia

EQRx, failed developer of low

Sen. Paul opposes bill to ban Chinese biotechs

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

knowledge

hotspot

hotspot

Wikipedia